Accession Number:

AD1095880

Title:

Neuroendocrine Differentiation and Enzalutamide Resistance in Prostate Cancer

Descriptive Note:

Technical Report,01 Sep 2017,31 Aug 2018

Corporate Author:

Rutgers Cancer Institute of New Jersey Piscataway United States

Personal Author(s):

Report Date:

2018-09-01

Pagination or Media Count:

10.0

Abstract:

The goal of the present proposal is to investigate the mechanism by which TCF4 regulates neuroendocrine differentiation NED and induces enzalutamide resistance in CRPC. In treating patients with CRPC, enzalutamide, the second-generation AR antagonist, has been considered a cornerstone of care. However, clinical benefits are limited to a median time of 4.8 months because resistance to enzalutamide inevitably emerges. Based on a body of preliminary data, we hypothesize that the transcription factor TCF4 is induced by AR-V7 and mediates, in part, enzalutamide resistance in CaP cells via the neuroendocrine marker, PTHrP. To test this hypothesis, two specific aims and four major tasks have been proposed. Of these objectives, major task 1 that focused on the role of AR and AR-V7 with TCF4 has been completed. We have found that the knockdown of AR-V7 reverses neuroendocrine differentiation and TCF4 expression. In addition, AR response element has been identified. Finally, overexpression of TCF4 has demonstrated neuroendocrine differentiation in vivo.

Subject Categories:

  • Medicine and Medical Research
  • Biochemistry

Distribution Statement:

APPROVED FOR PUBLIC RELEASE